194 related articles for article (PubMed ID: 20036387)
21. Predictive value of EGFR-PI3K-pAKT-mTOR-pS6 pathway in sinonasal squamous cell carcinomas.
Muñoz-Cordero MG; López F; García-Inclán C; López-Hernández A; Potes-Ares S; Fernández-Vañes L; Llorente JL; Hermsen M
Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(1):16-24. PubMed ID: 29573781
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 promotes the progression of human gliomas.
Zhang Y; Zhan H; Xu W; Yuan Z; Lu P; Zhan L; Li Q
Pathol Res Pract; 2011 Jan; 207(1):24-9. PubMed ID: 21087829
[TBL] [Abstract][Full Text] [Related]
23. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.
Capodanno A; Camerini A; Orlandini C; Baldini E; Resta ML; Bevilacqua G; Collecchi P
Hum Pathol; 2009 Oct; 40(10):1408-17. PubMed ID: 19428048
[TBL] [Abstract][Full Text] [Related]
24. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
[TBL] [Abstract][Full Text] [Related]
25. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA‑494 promotes the proliferation and migration of human glioma cancer cells through the protein kinase B/mechanistic target of rapamycin pathway by phosphatase and tensin homolog expression.
Han K; Li ZJ; Sun P
Oncol Rep; 2019 Jan; 41(1):351-360. PubMed ID: 30365133
[TBL] [Abstract][Full Text] [Related]
27. Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
Tu Y; He S; Fu J; Li G; Xu R; Lu H; Deng J
Clin Transl Oncol; 2012 Mar; 14(3):214-20. PubMed ID: 22374425
[TBL] [Abstract][Full Text] [Related]
28. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
[TBL] [Abstract][Full Text] [Related]
29. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS
Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007
[TBL] [Abstract][Full Text] [Related]
30. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
31. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.
Shen A; Wang Y; Zhao Y; Zou L; Sun L; Cheng C
Neurosurgery; 2009 Jul; 65(1):153-9; discussion 159-60. PubMed ID: 19574837
[TBL] [Abstract][Full Text] [Related]
32. Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis.
Gao H; Yu B; Yan Y; Shen J; Zhao S; Zhu J; Qin W; Gao Y
J Neurosurg; 2013 Apr; 118(4):846-53. PubMed ID: 23082878
[TBL] [Abstract][Full Text] [Related]
33. Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.
Chaux A; Schultz L; Albadine R; Hicks J; Kim JJ; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
Hum Pathol; 2012 Dec; 43(12):2129-37. PubMed ID: 22542128
[TBL] [Abstract][Full Text] [Related]
34. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma.
Lan F; Qing Q; Pan Q; Hu M; Yu H; Yue X
Cell Oncol (Dordr); 2018 Feb; 41(1):25-33. PubMed ID: 29076027
[TBL] [Abstract][Full Text] [Related]
35. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
[TBL] [Abstract][Full Text] [Related]
36. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome.
Panigrahi AR; Pinder SE; Chan SY; Paish EC; Robertson JF; Ellis IO
J Pathol; 2004 Sep; 204(1):93-100. PubMed ID: 15307142
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
38. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables.
Noh WC; Kim YH; Kim MS; Koh JS; Kim HA; Moon NM; Paik NS
Breast Cancer Res Treat; 2008 Aug; 110(3):477-83. PubMed ID: 17805960
[TBL] [Abstract][Full Text] [Related]
39. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.
Setsu N; Yamamoto H; Kohashi K; Endo M; Matsuda S; Yokoyama R; Nishiyama K; Iwamoto Y; Dobashi Y; Oda Y
Cancer; 2012 Mar; 118(6):1637-48. PubMed ID: 21837670
[TBL] [Abstract][Full Text] [Related]
40. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
